Pregabalin for the treatment of social anxiety disorder

Bibliography

• Schneier FR. Social anxiety disorder. N Engl J Med 2006;355:1029-36
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mental disorders. 5th edition. http://dsm.psychiatryonline.org [Accessed 3 October 2014]
   Google Scholar
• Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66:1351-61
   PubMed Web of Science ®Google Scholar
• Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008;29:115-29
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the national comorbidity survey replication. Psychol Med 2008;38:15-28
   PubMed Web of Science ®Google Scholar
• Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:1179-87
   PubMed Web of Science ®Google Scholar
• Beard C, Moitra E, Weisberg RB, et al. Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety 2010;27:839-45
   PubMed Web of Science ®Google Scholar
• Schneier FR, Johnson J, Hornig CD, et al. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-8
   PubMed Web of Science ®Google Scholar
• Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73
   PubMedGoogle Scholar
• Swinson RP; Clinical Practice Guideline Working Group. Management of anxiety disorders. Can J Psychiatry 2006;51:1-92
   Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and post-traumatic stress disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008;9:248-312
   PubMed Web of Science ®Google Scholar
• Rodebaugh TL, Holaway RM, Heimberg RG. The treatment of social anxiety disorder. Clin Psychol Rev 2004;24:883-908
   PubMed Web of Science ®Google Scholar
• Gould RA, Buckminister S, Pollack MH, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a meta-analysis. Clin Psychol Sci Pract 1997;4:291-306
   Web of Science ®Google Scholar
• van der Linden GJ, Stein DJ, van Balkom A. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000;15(Suppl 2):15-23
   PubMedGoogle Scholar
• Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a metaanalysis. J Clin Psychopharmacol 2001;21:311-23
   PubMed Web of Science ®Google Scholar
• Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003;6:427-42
   PubMed Web of Science ®Google Scholar
• Blanco C, Schneier FR, Schmidt AB, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 2003;18:29-40
   PubMed Web of Science ®Google Scholar
• Hedges DW, Brown BL, Shwalb DA, et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007;21:102-11
   PubMed Web of Science ®Google Scholar
• Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006;67(Suppl 12):20-6
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein MB. Double-blind placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65(2):244-8
   PubMed Web of Science ®Google Scholar
• Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67(3):286-95
   PubMed Web of Science ®Google Scholar
• Blanco C, Bragdon LB, Schneier FR, et al. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 2013;16(1):235-49
   PubMed Web of Science ®Google Scholar
• Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71(6):1058-67
   PubMed Web of Science ®Google Scholar
• Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-13
   PubMed Web of Science ®Google Scholar
• Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20:636-44
   PubMed Web of Science ®Google Scholar
• Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59:1111-18
   PubMed Web of Science ®Google Scholar
• Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6:317-23
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66(10):1270-8
   PubMed Web of Science ®Google Scholar
• Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 2008;8(2):235-57
   PubMedGoogle Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2-d (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50
   PubMed Web of Science ®Google Scholar
• Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013;9(1):105-15
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-6
   PubMed Web of Science ®Google Scholar
• Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-41
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapenti. Clin Pharmacokinet 2010;49(10):661-9
   PubMed Web of Science ®Google Scholar
• Sikka SC, Chen C, Almas M, et al. Pregabalin does not affect sperm production in healthy volunteers: a randomized, double-blind, placebo-controlled, noninferiority study. Pain Pract 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Herman AI, Waters AJ, McKee SA, et al. Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology (Berl) 2012;220(3):611-17
   PubMed Web of Science ®Google Scholar
• Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011;26(4):213-20
   PubMed Web of Science ®Google Scholar
• Greist JH, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol 2011;26(5):243-51
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24(2):141-9
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33
   PubMed Web of Science ®Google Scholar
• Heimberg RG, Horner KJ, Juster HR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212
   PubMed Web of Science ®Google Scholar
• Hamilton MA. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
   PubMed Web of Science ®Google Scholar
• Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. US Dept of Health, Education and Welfare; Rockville, MD: 1976
   Google Scholar
• Marks I, Mathews A. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263-7
   PubMed Web of Science ®Google Scholar
• Ware JEJr, Snow KK, Kosinski M, et al. SF-36 Health survey: manual and interpretation guide. The Health Institute, New England Medical Center; Boston, MA: 1993
   Google Scholar
• Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorders: the Sheehan disability scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78-82
   PubMed Web of Science ®Google Scholar
• Davidson JR, Potts NL, Richichi EA, et al. The brief social phobia scale. J Clin Psychiatry 1991;52(Suppl):48-51
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JRT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000;176:379-86
   PubMed Web of Science ®Google Scholar
• Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin 2013;29(10):1223-30
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Martinotti G, Tedeschi D, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol 2010;25(3):268-75
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010;24(9):1367-74
   PubMed Web of Science ®Google Scholar
• Schry AR, White SW. Understanding the relationship between social anxiety and alcohol use in college students: a meta-analysis. Addict Behav 2013;38(11):2690-706
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
   PubMed Web of Science ®Google Scholar
• Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 2012;21(7):1019-29
   PubMed Web of Science ®Google Scholar
• Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014;28(6):491-6
   PubMed Web of Science ®Google Scholar
• Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs 2012;21(9):1243-5
   PubMed Web of Science ®Google Scholar
• Martinotti G, Lupi M, Sarchione F, et al. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des 2013;19(35):6367-74
   PubMed Web of Science ®Google Scholar